Current management of advanced non-small cell lung cancer: Targeted therapy

Seminars in Oncology

Volumn 32, Issue 3 SOPEC. ISS, 2005, Pages 315-328

  Isobe, Takeshi ^a   Herbst, Roy S ^a   Onn, Amir ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; AE 941; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEXAROTENE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CL 1033; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; ISIS 3521; LONAFARNIB; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; N ACETYLCOLCHINOL PHOSPHATE; NAVELBINE; OBLIMERSEN; PACLITAXEL; PLATINUM; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; RETINOID; SEMAXANIB; THALIDOMIDE; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN;

ACNE; ALLERGIC REACTION; ANOREXIA; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DYSPNEA; EPISTAXIS; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; METASTASIS; NAUSEA; PAIN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; PRURITUS; QT PROLONGATION; RASH; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; VOMITING;

EID: 20644441106     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.02.016     Document Type: Article

References (123)

1. A. Jemal, T. Murray, E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. P.A. Bunn Jr Chemotherapy for advanced non-small-cell lung cancer Who, what, when, why? J Clin Oncol 20 suppl 18 2002 23s 33s
3. J. Mendelsohn Targeting the epidermal growth factor receptor for cancer therapy J Clin Oncol 20 suppl 18 2002 1s 13s
4. V. Grünwald, M. Hidalgo Developing inhibitors of the epidermal growth factor receptor for cancer treatment J Natl Cancer Inst 95 2003 851 867
5. R. Kerbel, J. Folkman Clinical translation of angiogenesis inhibitors Nat Rev Cancer 2 2002 727 739
6. E. Ruoslahti Specialization of tumour vasculature Nat Cancer Rev 2 2002 83 90
7. J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 103 2000 211 225
8. M.A. Olayioye, R.M. Neve, H.A. Lane The ErbB signaling network Receptor heterodimerization in development and cancer EMBO J 19 2000 3159 3167
9. H. Dazzi, P.S. Hasleton, N. Thatcher Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival Br J Cancer 59 1989 746 749
10. M. Tateishi, T. Ishida, S. Kohdono Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma Surg Oncol 3 1994 109 113
11. U. Pastorino, S. Andreola, E. Tagliabue Immunocytochemical markers in stage I lung cancer Relevance to prognosis J Clin Oncol 15 1997 2858 2865
12. V. Rusch, D. Klimstra, E. Venkatraman Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression Clin Cancer Res 3 1997 515 522
13. T.M. Greatens, G.A. Niehans, J.B. Rubins Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 157 1998 1093 1097
14. P. Pfeiffer, E. Nexo, S.M. Bentzen Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer Comparisons with immunohistochemistry, clinicopathological features and prognosis Br J Cancer 78 1998 96 99
15. M. Volm, W. Rittgen, P. Drings Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas Br J Cancer 77 1998 663 669
16. G. Fontanini, M. De Laurentiis, S. Vignati Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer Amphiregulin and microvessel count are independent prognostic indicators of survival Clin Cancer Res 4 1998 241 249
17. X.L. Fu, X.Z. Zhu, D.R. Shi Study of prognostic predictors for non-small cell lung cancer Lung Cancer 23 1999 143 152
18. T.A. D'Amico, M. Massey, J.E. Herndon II A biologic risk model for stage I lung cancer Immunohistochemical analysis of 408 patients with the use of ten molecular markers J Thorac Cardiovasc Surg 117 1999 736 743
19. Y. Ohsaki, S. Tanno, Y. Fujita Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression Oncol Rep 7 2000 603 607
20. G. Cox, J.L. Jones, K.J. O'Byrne Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer Clin Cancer Res 6 2000 2349 2355
21. W.W. Lai, F.F. Chen, M.H. Wu Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer Ann Thorac Surg 72 2001 1868 1876
22. T. Kanematsu, S. Yano, H. Uehara Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients Oncol Res 13 2003 289 298
23. F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Jr Epidermal growth factor receptor in non-small-cell lung carcinomas Correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 2003 3798 3807
24. A. Onn, A.M. Correa, M. Gilcrease Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer Clin Cancer Res 10 2004 136 143
25. P.T. Reissmann, H. Koga, R.A. Figlin Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer J Cancer Res Clin Oncol 125 1999 61 70
26. A.P. Meert, B. Martin, P. Delmotte The role of EGF-R expression on patient survival in lung cancer A systematic review with meta-analysis Eur Respir J 20 2002 975 981
27. M.W. Pedersen, M. Meltorn, L. Damstrup The type III epidermal growth factor receptor mutation Ann Oncol 12 2001 745 760
28. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness fo non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
29. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
30. J. Mendelsohn, J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799
31. R.S. Herbst, C.J. Langer Epidermal growth factor receptors as a target for cancer treatment The emerging role of IMC-C225 in the treatment of lung and head and neck cancers Semin Oncol 29 2002 27 36
32. F. Robert, G. Blumenschein, K. Dicke Phase IB/IIIA study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced stage IV non-small cell lung cancer Proc Am Soc Clin Oncol 22 2003 643 (abstr)
33. K. Kelly, N. Hanna, A. Rosenberg A multicenter phase I/II study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with paclitaxel and carboplatin in patients with IV non-small cell lung cancer Proc Am Soc Clin Oncol 22 2003 644 (abstr)
34. E. Kim, A. Mauer, H. Tran A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer Final report Proc Am Soc Clin Oncol 22 2003 642 (abstr)
35. U. Gatzemeier, R. Rosell, R. Ramlau Cetuximab (Erbitux) in combination with cisplatin/vinorelbine vs cisplatin/vinorelbine alone in the first-line treatment of patients with epidermal growth factor receptor-expressing advanced non-small cell lung cancer Proc Am Soc Clin Oncol 22 2003 642 (abstr)
36. R. Rosell, C. Daniel, R. Ramlau Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 2004 618a
37. R.S. Herbst, M.S. Kies ZD1839 (Iressa) in non-small cell lung cancer Oncologist 7 suppl 4 2002 9 15
38. R.S. Herbst Erlotinib (Tarceva) An update on the clinical trial program Semin Oncol 30 suppl 7 2003 34 46
39. M. Fukuoka, S. Yano, G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237 2246
40. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer A randomized trial JAMA 290 2003 2149 2158
41. J.E. Dancey, B. Freidlin Targeting epidermal growth factor receptor-Are we missing the mark? Lancet 362 2003 62 64
42. G. Giaccone, R.S. Herbst, C. Manegold Gefitinib (ZD1839) in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer A phase III trial (INTACT 1) J Clin Oncol 22 2004 777 784
43. R.S. Herbst, G. Giaccone, J.H. Schiller Gefitinib (ZD1839) in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer A phase III trial (INTACT 2) J Clin Oncol 22 2004 785 794
44. U. Gatzemeier, A. Pluzanska, A. Szczesna Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer Proc Am Soc Clin Oncol 22 2004 7010
45. R.S. Herbst, D. Drager, R. Herman TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer Proc Am Soc Clin Oncol 22 2004 7011
46. F.A. Shepherd, J. Pereira, T.E. Ciuleanu A randomized placebo-controlled trial of erlotinib in patients with non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial J Clin Oncol 22 2004 145
47. W. Pao, V.A. Miller Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer Current knowledge and future directions J Clin Oncol 23 2005 2268 2556
48. H. Shigematsu Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
49. M. Pegram, S. Hsu, G. Lewis Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 1999 2241 2251
50. J. Schiller, C.J. Langer, A. Thor Trastuzumab in combination with paclitaxel/carboplatin advanced non-small cell lung cancer Final report of ECOG 2598 Proc Am Soc Clin Oncol 22 2003 648 (abstr)
51. U. Gatzemeier, G. Groth, C. Butts Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer Ann Oncol 15 2004 19 27
52. R.G. Zinner, J. Kim, R.S. Herbst Non-small cell lung cancer clinical trials with trastuzumab their foundation and preliminary results Lung Cancer 37 2002 17 27
53. M. Huncharek, J. Muscat, J.F. Geschwind K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer A combined analysis of 881 cases Carcinogenesis 20 1999 1507 1510
54. J. Downward Ras signaling and apoptosis Curr Opin Genet Dev 8 1998 9 54
55. A.A. Adjei An overview of farnesyltransferase inhibitors and their role in lung cancer therapy Lung Cancer 41 2003 55 62
56. Web page accessed 2/5/04: http://www.schering-plough.com/schering-plough/ news/release.jsp?releaseID=492402
57. M. Hidalgo, S.G. Eckhardt Development of matrix metalloproteinase inhibitors in cancer therapy J Natl Cancer Inst 93 2001 178 193
58. E. Laack, A. Kohler, C. Kugler Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer Ann Oncol 13 2002 1550 1557
59. M. Smylie, R. Mercier, D. Aboulafia Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer Proc Am Soc Clin Oncol 20 2001 307 (abstr)
60. D. Bissett, J. Pawel, R. Mercier Phase III study of the matrix metalloprotease inhibitor prinomastat in combination with gemcitabine and cisplatin in non-small cell lung cancer Proc Am Soc Clin Oncol 21 2002 296 (abstr)
61. B. Franqois, P. Champagne, W. Evans Phase I/II trials on the safety, tolerability and efficacy of Æ-941 (Neovastat) in patients with solid tumors Proc Am Soc Clin Oncol 20 2001 277 (abstr)
62. N.B. Leighl, F. Shepherd, L. Pazares Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC) NCIC-CTG BR.18 J Clin Oncol 22 suppl 2004 (abstr)
63. H.C. Swannie, S.B. Kaye Protein kinase C inhibitors Curr Oncol Rep 4 2002 37 46
64. A. Yuen, R. Advani, G. Fisher Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer Proc Am Soc Clin Oncol 19 2001 167 (abstr)
65. P. Ritch, R. Belt, S. George Phase I/II trial of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha with cisplatin and gemcitabine in advanced non-small cell lung cancer Proc Am Soc Clin Oncol 21 2002 1233 (abstr)
66. T.J. Lynch, R. Raju, M. Lind A. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report Proc Am Soc Clin Oncol 22 2003 623 (abstr)
67. P. Chambon The retinoid signaling pathway molecular and genetic analyses Semin Cell Biol 5 1994 115 125
68. S.M. Lippman, J.J. Lee, D.D. Karp Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer J Natl Cancer Inst 93 2001 605 618
69. F.R. Khuri, J.R. Rigas, R.A. Figlin Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer J Clin Oncol 19 2001 2626 2637
70. J. Folkman Tumor angiogenesis Therapeutic implications N Engl J Med 285 1971 1182 1186
71. G. Bergers, L.E. Benjamin Tumorigenesis and the angiogenic switch Nat Rev 3 2003 401 410
72. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
73. D.R. Senger, C.A. Perruzzi, J. Feder A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines Cancer Res 46 1986 5629 5632
74. Y. Ohta, Y. Endo, M. Tanaka Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer Clin Cancer Res 2 1996 1411 1416
75. M. Volm, R. Koomagi, J. Mattern Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer Int J Cancer 74 1997 64 68
76. H. Imoto, T. Osaki, S. Taga Vascular endothelial growth factor expression in non-small-cell lung cancer Prognostic significance in squamous cell carcinoma J Thorac Cardiovasc Surg 115 1998 1007 1014
77. T. Shibusa, N. Shijubo, S. Abe Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma Clin Cancer Res 4 1998 1483 1487
78. A. Giatromanolaki, M.I. Koukourakis, S. Kakolyris Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer Clin Cancer Res 4 1998 3017 3024
79. G. Fontanini, L. Boldrini, S. Vignati Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma Eur J Cancer 34 1998 718 723
80. H. Aikawa, H. Takahashi, S. Fujimura Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer Anticancer Res 19 1999 4305 4309
81. M. Volm, R. Koomagi, J. Mattern PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis Anticancer Res 19 1999 651 655
82. Y. Ohta, Y. Tomita, M. Oda Tumor angiogenesis and recurrence in stage I non-small cell lung cancer Ann Thorac Surg 68 1999 1034 1038
83. N. Shijubo, T. Uede, S. Kon Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma Am J Respir Crit Care Med 160 1999 1269 1273
84. T. Yano, S. Tanikawa, T. Fujie Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer Eur J Cancer 36 2000 601 609
85. D. Masuya, C. Huang, D. Liu The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in non-small cell lung carcinoma patients Cancer 92 2001 2628 2638
86. D. Toomey, G. Smyth, C. Condron Immune function, telomerase, and angiogenesis in patients with primary, operable non-small cell lung carcinoma Tumor size and lymph node status remain the most important prognostic features Cancer 92 2001 2648 2657
87. R. Baillie, J. Carlile, N. Pendleton Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer J Clin Pathol 54 2001 116 120
88. H. Han, J.F. Silverman, T.S. Santucci Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis Ann Surg Oncol 8 2001 72 79
89. K. Minami, Y. Saito, H. Imamura Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung Lung Cancer 38 2002 51 57
90. N. Ferrara, H.P. Gerber, J. LeCouter The biology of VEGF and its receptors Nature Med 9 2003 669 676
91. S.A. Stacker, M.G. Achen, L. Jussila Lymphangiogenesis and cancer metastasis Nat Rev Cancer 2 2002 573 583
92. F.A. Scappaticci Mechanisms and future directions for angiogenesis-based cancer therapies J Clin Oncol 20 2002 3906 3927
93. E.S. Kim, R.S. Herbst Angiogenesis inhibitors in lung cancer Curr Oncol Rep 4 2002 325 333
94. R.S. Herbst, M. Hidalgo, A.S. Pierson Angiogenesis inhibitors in clinical development for lung cancer Semin Oncol 29 suppl 4 2002 66 77
95. L.G. Presta, H. Chen, S.J. O'Connor Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 1997 4593 4599
96. K. Margolin, M.S. Gordon, E. Holmgren Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer Pharmacologic and long-term safety data J Clin Oncol 19 2001 851 856
97. M.S. Gordon, K. Margolin, M. Talpaz Phase I safety and pharmachokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 2001 843 850
98. D.H. Johnson, L. Fehrenbacher, W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
99. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
100. J.C. Yang, L. Haworth, R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
101. T.A. Fong, L.K. Shawver, L. Sun SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types Cancer Res 59 1999 99 106
102. B.C. Kuenen, L. Rosen, E.F. Smit Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors J Clin Oncol 15 2002 1657 1667
103. W. Wu, T. Isobe, S. Itasaka ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer Proc Am Assoc Cancer Research 2004
104. H. Hurwitz, S.N. Holden, S.G. Eckhardt Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling in patients with solid tumors Proc Am Soc Clin Oncol 21 2002 82 (abstr)
105. H. Minami, H. Ebi, M. Tahara A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors Proc Am Soc Clin Oncol 21 2003 194 (abstr)
106. P.D. Davis, G.J. Dougherty, D.C. Blakey ZD6126 A novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res 62 2002 7247 7253
107. H. Goto, S. Yano, H. Zhang Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice Cancer Res 62 2002 3711 3715
108. S.M. Gadgeel, P.M. LoRusso, A.J. Wozniak A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors Proc Am Soc Clin Oncol 21 2002 110a (abstr)
109. M.S. O'Reilly, T. Boehm, Y. Shing Endostatin An endogenous inhibitor of angiogenesis and tumor growth Cell 88 1997 277 285
110. R.S. Herbst, K.R. Hess, H.T. Tran Phase I study of recombinant human endostatin in patients with advanced solid tumors J Clin Oncol 20 2002 3792 3803
111. R.S. Herbst, D.H. Johnson, E. Mininberg Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
112. G. Steinbach, P.M. Lynch, R.K. Phillips The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 2000 1946 1952
113. T. Hida, K. Kozaki, H. Muramatsu Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines Clin Cancer Res 6 2000 2006 2011
114. N. Altorki, R. Keresztes, J. Port Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer Proc Am Soc Clin Oncol 21 2002 26 (abstr)
115. I. Csiki, T. Dang, A. Gonzalez Cyclooxygenase-2 (COX-2) inhibition + docetaxel (Txt) in recurrent non-small cell lung cancer (NSCLC) Preliminary results of a phase II trial (THO-0054) Proc Am Soc Clin Oncol 21 2002 1187 (abstr)
116. L.A. Liotta, E.C. Kohn The microenvironment of the tumor-host interface Nature 411 2001 375 379
117. I.J. Fidler The organ microenvironment and cancer metastasis Differentiation 70 2002 498 505
118. E. Fox, G.A. Curt, F.M. Balis Clinical trial design for target-based therapy Oncologist 7 2002 401 409
119. B. Goldman For investigational targeted drugs, combination trials pose challenges J Natl Cancer Inst 95 2003 1744 1746
120. C.H. Baker, D. Kedar, M.F. McCarty Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas Am J Pathol 161 2002 929 938
121. J. Brabender, K.D. Danenberg, R. Metzger Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival Clin Cancer Res 7 2001 1850 1855
122. E.D. Mininberg, R.S. Herbst, T. Henderson Phase I/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer Proc Am Soc Clin Oncol 22 2003 627 (abstr)
123. A. Onn, T. Isobe, S. Itasaka Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice Clin Cancer Res 9 2003 5532 5539